tiprankstipranks
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
US Market
ARQT
Arcutis Biotherapeutics
RESEARCH TOOLSreports

Arcutis Biotherapeutics (ARQT) Stock News & Sentiment

Compare
959 Followers
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
Premium
Company Announcements
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
15d ago
ARQT
Arcutis (ARQT) Earnings Call Signals Scaled Growth
Premium
Company Announcements
Arcutis (ARQT) Earnings Call Signals Scaled Growth
20d ago
ARQT
Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating
Premium
Ratings
Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating
27d ago
ARQT
Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target
Premium
Ratings
Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target
27d ago
ARQT
Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating
Premium
Ratings
Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating
27d ago
ARQT
ARQT Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ARQT Earnings this Week: How Will it Perform?
30d ago
ARQT
Arcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
Premium
Ratings
Arcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
2M ago
ARQT
More ARQT News >

ARQT News on the Web

Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
TipRanks News
Bullish
Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream
TipRanks News
Bullish
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
TipRanks News
Bullish
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT)
TipRanks News
Neutral
Arcutis Biotherapeutics (ARQT) Elevates Legal Leader to Executive Role
GuruFocus News
Neutral
Arcutis announces promotion of Matsuda to EVP, Chief Legal Officer
TipRanks News
Bullish
Arcutis (ARQT) Earnings Call Signals Scaled Growth
TipRanks News
Bullish
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
GuruFocus News
Bearish

News Score - Last 7 Days

Neutral
ARQT
Sector Average
Media Buzz
This Week1 articles
Weekly Average9.5 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARQT’s Media Buzz Sentiment?
1 articles about ARQT were published this week. In an average week, 9.5 articles are published.
    What is ARQT’s weekly average amount of articles?
    In an average week, 9.5 articles about ARQT are published.
      What is ARQT’s News Sentiment?
      100% of articles about ARQT were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        HYPRHyperfine
        OVIDOvid Therapeutics
        ALMSAlumis Inc.
        INNMFAmplia Therapeutics
        PBHPrestige Consumer Healthcare
        Showing the stocks with the most bullish news sentiment over the past week